№ files_lp_3_process_7_089214
File format: docx
Character count: 2700
File size: 31 KB
Structured form used for healthcare providers to refer patients with mild COVID-19 at high risk for progression to monoclonal antibody treatment under Health Canada’s interim authorization.
Year:
2026
Region / City:
Canada, multiple cities
Subject:
COVID-19 treatment eligibility
Document Type:
Medical referral form
Organization / Institution:
Health Canada; regional hospitals
Author:
Clinicians completing referral
Target Audience:
Healthcare providers and eligible patients
Eligibility Criteria:
Adults and pediatric patients ≥12 years, ≥40 kg, at high risk of severe COVID-19
Treatment Window:
Within 7 days of symptom onset
Authorization:
Interim authorization (Interim Order) by Health Canada
Patient Data Fields:
Name, Date of birth, Allergies, Address, Contact information, Health Card Number
Clinical Criteria:
Symptomatic status, vaccination status, comorbidities, immunosuppression, prior COVID-19 infection
Referral Confirmation:
Clinician attestation with signature, date, and College number
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Document Type:
Supplementary scientific figure description
Study Subject:
Cynomolgus monkeys
Sample Size:
n=3 per group
Test Article:
MYTX-011
Dose:
6.0 mg/kg single dose
Analytes Measured:
Total ADC, total mAb, free MMAE
Biological Matrix:
Blood
Analytical Method:
LC-MS/MS assays
Research Context:
Pharmacokinetic measurement following administration of an antibody–drug conjugate
Key Observation:
Similar levels of total mAb and total ADC indicating high stability of site-specific conjugation
Year:
2022
Region / City:
Not specified
Topic:
Research proposals related to the MAB Programme and Biosphere Reserves
Document type:
Application form
Institution:
UNESCO
Author:
Not specified
Target audience:
Young scientists applying for the MAB Young Scientists Awards
Action period:
Not specified
Approval date:
Not specified
Amendment date:
Not specified
Year:
Not specified
Subject:
Monoclonal antibody uptake in cancer cell lines
Cell lines:
EBC-1 (cMETHigh); NCI-H1975 (cMETMod); NCI-H2122 (cMETLow)
Methodology:
Flow cytometry
Treatment duration:
24 hours
Analytes:
Parent mAb and MYTX-011 mAb complexed with Fab-pHrodo
Experiment type:
In vitro study
Replication:
Three independent replicates
Significance thresholds:
***<0.001; ****<0.0001
Field:
Biomedical research
Note:
Year
Region / City:
United States
Topic:
Pharmaceutical naming and regulatory processes
Document type:
Application form
Organization / Institution:
United States Adopted Names Council, American Medical Association
Target audience:
Pharmaceutical companies, researchers, regulatory authorities
Year:
2023
Region / City:
Not specified
Topic:
Monoclonal antibody sequences, growth rate inhibition in cell models
Document type:
Research Supplementary Material
Organization / Institution:
Not specified
Author:
Not specified
Target audience:
Researchers, biomedical professionals
Effective period:
Not specified
Approval date:
Not specified
Modification date:
Not specified
Section:
Supplemental Methods
Field:
Immunology and Hematologic Malignancies
Experimental focus:
B7-H3 CAR-T cells in acute myeloid leukemia (AML)
Monoclonal antibodies:
Anti-human CD markers and related reagents for flow cytometry
Suppliers:
Becton-Dickinson (BD) Biosciences; Miltenyi Biotec; BioLegend; Jackson ImmunoResearch Labs
Cell lines:
THP1; U937; HL-60; Kasumi-1; OCI-AML2; OCI-AML3
Primary samples:
DFAM-6855; CBAM-44728 from Public Repository of Xenografts (PRoXe), Dana-Farber Cancer Institute
Biological material:
Primary AML blasts; donor PBMCs; buffy coats from healthy volunteers
Vector system:
SFG retroviral vector with MoMLV gag-pol and RD114 envelope
Transduction method:
Retronectin-coated plates with retroviral supernatant
Cell expansion cytokines:
IL7; IL15
Statistical methods:
Mann Whitney test; one-way ANOVA with Holm-Sidak adjustment; Chi-square test
Software:
Prism version 8 (GraphPad)
Sample origin:
Bone marrow and peripheral blood from AML patients
Animal model:
NSG mice for in vivo expansion of xenografts
Culture conditions:
RPMI-1640 medium with fetal bovine serum, L-glutamine, penicillin, and streptomycin
Year:
2026
Location:
United States
Subject:
Immunology, Monoclonal Antibodies, Mast Cell Biology
Document Type:
Research Supplement / Methods Section
Institution:
Kolltan Pharmaceuticals
Authors:
London et al.
Target Audience:
Scientific researchers in immunology and pharmacology
Experimental Period:
2026
Cell Types:
Human CD34+ progenitor cells, PBMCs, mast cells
Key Techniques:
Flow cytometry, antibody assays, cell differentiation, KIT phosphorylation
Reagents:
KTN0158, KTN0062C, KTN0209, KTN0235, Imatinib, Nilotinib, IL-3, IL-6, SCF, LDL
Year:
2023
Region / City:
Beijing, China
Subject:
Allergic diseases, monoclonal antibody therapy, clinical trials
Document Type:
Supplementary data
Institution:
Capital Medical University, Department of Immunology
Authors:
Yan Chen, Wei Wang, Huihui Yuan, Yan Li, Zhe Lv, Ye Cui, Jie Liu, Sun Ying
Target Population:
Children, adolescents, and adults with allergic asthma
Trial Duration:
12–60 weeks
Primary Outcomes:
Treatment safety, efficacy, quality of life, pulmonary function, IgE levels
Sample Size Range:
19–4308 participants
Medications Studied:
Omalizumab
Study Design:
Controlled clinical trials with specific inclusion criteria for allergic asthma patients
Year:
2026
Research area:
Molecular biology / Cancer research
Document type:
Supplementary figure
Institution:
Unspecified research laboratory
Experimental models:
A549 and HCT116 cancer cell lines
Methods:
Monoclonal antibody production, siRNA knockdown, Simple Western analysis
Compounds tested:
DMSO, M8891
Duration of treatment:
24 hours
Observation period:
96 hours post-knockdown
Controls:
Non-targeting siRNA, γ-tubulin loading control
Visualization software:
Protein Simple Compass
Year:
2024
Region / City:
Europe
Topic:
Preclinical drug safety assessment
Institution:
Master’s programme, Drug Innovation
Author:
Benedetta Boscolo Todaro
Supervisors:
Hsiao-Tzu Chien, Marieke de Bruin, Peter Van Meer
Target audience:
Regulatory scientists, pharmacologists
Study period:
October 2024 – April 2025
Data analyzed:
42 monoclonal antibodies submitted for EMA approval (2017–2024)
Methodology:
Weight-of-evidence approach, literature review, short-term toxicity studies
Ethical considerations:
Reduction of animal testing, alignment with 3Rs principles